The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mevrometostat (PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 trial.
 
Michael Schweizer
Consulting or Advisory Role - AstraZeneca; FibroGen; Janssen; Pfizer; Sanofi
Research Funding - Ambrx (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Epigenetix (Inst); Immunomedics (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SignalOne Bio (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenith Epigenetics (Inst)
 
Jayeta Chakrabarti
Employment - Pfizer
 
Sujata Narayanan
Employment - Calithera Biosciences; Pfizer
Stock and Other Ownership Interests - Calithera Biosciences; Pfizer
 
Stella Lin
Employment - Pfizer